Literature DB >> 16546684

Automatic synthesis of 16 alpha-[(18)F]fluoro-17beta-estradiol using a cassette-type [(18)F]fluorodeoxyglucose synthesizer.

Tetsuya Mori1, Shingo Kasamatsu, Christoph Mosdzianowski, Michael J Welch, Yoshiharu Yonekura, Yasuhisa Fujibayashi.   

Abstract

16 alpha-[(18)F]fluoro-17beta-estradiol ([(18)F]FES) is a radiotracer for imaging estrogen receptors by positron emission tomography. We developed a clinically applicable automatic preparation system for [(18)F]FES by modifying a cassette-type [(18)F]fluorodeoxyglucose synthesizer. Two milligrams of 3-O-methoxymethyl-16,17-O-sulfuryl-16-epiestriol in acetonitrile was heated at 105 degrees C for 10 min with dried [(18)F]fluoride. The resultant solution was evaporated and hydrolyzed with 0.2 N HCl in 90% acetonitrile/water at 95 degrees C for 10 min under pressurized condition. The neutralization was carried out with 2.8% NaHCO(3), and then the high-performance liquid chromatography (HPLC) purification was performed. The desired radioactive fraction was collected and the solvent was replaced by 10 ml of saline, and then passed through a 0.22-microm filter into a pyrogen-free vial as the final product. The HPLC purification data demonstrated that [(18)F]FES was synthesized with a yield of 76.4+/-1.9% (n=5). The yield as the final product for clinical use was 42.4+/-3.2% (n=5, decay corrected). The total preparation time was 88.2+/-6.4 min, including the HPLC purification and the solvent replacement process. The radiochemical purity of the final product was >99%, and the specific activity was more than 111 GBq/micromol. The final product was stable for more than 6 h in saline containing sodium ascorbate. This new preparation system enables us to produce [(18)F]FES safe for clinical use with high and reproducible yield.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546684     DOI: 10.1016/j.nucmedbio.2005.11.002

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  18 in total

1.  Basic evaluation of FES-hERL PET tracer-reporter gene system for in vivo monitoring of adenoviral-mediated gene therapy.

Authors:  Talakad Goolaiah Lohith; Takako Furukawa; Tetsuya Mori; Masato Kobayashi; Yasuhisa Fujibayashi
Journal:  Mol Imaging Biol       Date:  2008-06-12       Impact factor: 3.488

2.  Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals.

Authors:  Dong Zhou; Mai Lin; Norio Yasui; Mohammed H Al-Qahtani; Carmen S Dence; Sally Schwarz; John A Katzenellenbogen
Journal:  J Labelled Comp Radiopharm       Date:  2014-02-17       Impact factor: 1.921

3.  Highlighting the Versatility of the Tracerlab Synthesis Modules. Part 1: Fully Automated Production of [F]Labelled Radiopharmaceuticals using a Tracerlab FX(FN).

Authors:  Xia Shao; Raphaël Hoareau; Brian G Hockley; Louis J M Tluczek; Bradford D Henderson; Henry C Padgett; Peter J H Scott
Journal:  J Labelled Comp Radiopharm       Date:  2011-05-30       Impact factor: 1.921

4.  Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.

Authors:  Yoshio Yoshida; Yasushi Kiyono; Tetsuya Tsujikawa; Tetsuji Kurokawa; Hidehiko Okazawa; Fumikazu Kotsuji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-08       Impact factor: 9.236

5.  18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT.

Authors:  Cheng Liu; Chengcheng Gong; Shuai Liu; Yingjian Zhang; Yongping Zhang; Xiaoping Xu; Huiyu Yuan; Biyun Wang; Zhongyi Yang
Journal:  Oncologist       Date:  2019-07-23

6.  Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.

Authors:  Tetsuya Tsujikawa; Yoshio Yoshida; Yasushi Kiyono; Tetsuji Kurokawa; Takashi Kudo; Yasuhisa Fujibayashi; Fumikazu Kotsuji; Hidehiko Okazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

7.  The clinical value of 18F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies.

Authors:  Ziyi Yang; Yizhao Xie; Cheng Liu; Xin Liu; Shaoli Song; Yingjian Zhang; Rui Ge; Biyun Wang; Zhongyi Yang
Journal:  Quant Imaging Med Surg       Date:  2021-09

8.  Prognostic Value of 16α-18F-Fluoro-17β-Estradiol PET as a Predictor of Disease Outcome in Endometrial Cancer: A Prospective Study.

Authors:  Shizuka Yamada; Hideaki Tsuyoshi; Makoto Yamamoto; Tetsuya Tsujikawa; Yasushi Kiyono; Hidehiko Okazawa; Yoshio Yoshida
Journal:  J Nucl Med       Date:  2020-10-02       Impact factor: 10.057

9.  An in vitro and in vivo evaluation of a reporter gene/probe system hERL/(18)F-FES.

Authors:  Chunxia Qin; Xiaoli Lan; Jiang He; Xiaotian Xia; Yueli Tian; Zhijun Pei; Hui Yuan; Yongxue Zhang
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

10.  Synthesis of Clinical-Grade [(18)F]-Fluoroestradiol as a Surrogate PET Biomarker for the Evaluation of Estrogen Receptor-Targeting Therapeutic Drug.

Authors:  Manish Dixit; Jianfeng Shi; Ling Wei; George Afari; Sibaprasad Bhattacharyya
Journal:  Int J Mol Imaging       Date:  2013-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.